Degradation of enkephalin and enkephalinamide by neuroblastoma x glioma hybrid cells as studied by 13C n.m.r.
13C n.m.r. and thin-layer chromatography were used to monitor the degradation of methionine-enkephalinamide in the presence of neuroblastoma x glioma hybrid cells (NG 108-15) and membranes. Puromycin and trypsin treatment failed to protect enkephalinamide from degradation over long periods of time (up to 24 hours). The major degradation products of [3[2-13C]glycine] methionine-enkephalinamide observed by 13 C n.m.r. showed glycine-3 in a non-terminal position, an N-terminal position and free glycine. A minor component showed glycine-3 in a C-terminal position.
D002462:Cell Membrane / Q000378:metabolism; D002855:Chromatography, Thin Layer; D004723:Endorphins / Q000378:metabolism*; D004744:Enkephalin, Methionine / Q000031:analogs & derivatives*; D004745:Enkephalins / Q000378:metabolism*; D005910:Glioma / Q000378:metabolism*; D006801:Humans; D006822:Hybrid Cells / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy; D009447:Neuroblastoma / Q000378:metabolism*; D011691:Puromycin / Q000494:pharmacology; D014357:Trypsin / Q000494:pharmacology
D004723:Endorphins; D004745:Enkephalins; D011691:Puromycin; D004744:Enkephalin, Methionine; C021055:Met-enkephalinamide; D014357:Trypsin